Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
STVN 
Stevanato Group SpA (STVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: STVN (1-star) is a SELL. SELL since 4 days. Simulated Profits (-10.23%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.62
1 Year Target Price $28.62
| 6 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.89% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.58B USD | Price to earnings Ratio 42.88 | 1Y Target Price 28.62 |
Price to earnings Ratio 42.88 | 1Y Target Price 28.62 | ||
Volume (30-day avg) 11 | Beta 0.57 | 52 Weeks Range 17.07 - 28.00 | Updated Date 10/18/2025 |
52 Weeks Range 17.07 - 28.00 | Updated Date 10/18/2025 | ||
Dividends yield (FY) 0.22% | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.75% | Operating Margin (TTM) 15.03% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 9.89% |
Valuation
Trailing PE 42.88 | Forward PE 33.22 | Enterprise Value 7573353691 | Price to Sales(TTM) 5.75 |
Enterprise Value 7573353691 | Price to Sales(TTM) 5.75 | ||
Enterprise Value to Revenue 5.64 | Enterprise Value to EBITDA 32.46 | Shares Outstanding 49691433 | Shares Floating 48894417 |
Shares Outstanding 49691433 | Shares Floating 48894417 | ||
Percent Insiders 1.66 | Percent Institutions 112.41 |
Upturn AI SWOT
Stevanato Group SpA
Company Overview
History and Background
Stevanato Group was founded in 1949 in Italy. It began as a glass manufacturer and evolved into a leading provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. Key milestones include expansion into plastic components, automation equipment, and global expansion.
Core Business Areas
- Glass Primary Packaging: Manufactures glass vials, ampoules, cartridges, and syringes for pharmaceutical use.
- Plastic Solutions: Provides plastic drug delivery systems, diagnostic consumables, and medical devices.
- Engineering: Designs and manufactures equipment for processing glass tubing into pharmaceutical containers.
- Analytical Services: Testing of pharmaceutical components for different properties.
Leadership and Structure
Franco Stevanato serves as the Executive Chairman. Marco Dal Lago is the Chief Executive Officer. The company has a board of directors and operates with a global structure, with manufacturing facilities and sales offices across multiple countries.
Top Products and Market Share
Key Offerings
- Glass Vials: Glass vials for injectable drugs. Stevanato Group is a major player in this market, capturing a significant market share (estimated 20-25%). Competitors include Schott, Gerresheimer, and Nipro.
- Prefillable Syringes: Ready-to-use syringes for drug delivery. Competitors include Becton Dickinson (BDX), West Pharmaceutical Services, and SCHOTT.
- Cartridges for Insulin Pens: Glass Cartridges for Insulin Pens. Competitors include Becton Dickinson (BDX), West Pharmaceutical Services, and SCHOTT.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is experiencing growth driven by factors such as the increasing demand for injectable drugs, the rise of biologics, and stringent regulatory requirements for drug containment. There is also increasing focus on sustainable products in the sector.
Positioning
Stevanato Group is positioned as a leading provider of high-value solutions in pharmaceutical packaging and drug delivery. Its competitive advantages include its integrated approach (glass, plastic, equipment), its focus on quality and innovation, and its strong relationships with pharmaceutical companies.
Total Addressable Market (TAM)
The TAM for pharmaceutical packaging and drug delivery is estimated to be in the hundreds of billions of dollars globally. Stevanato Group is well-positioned to capture a growing share of this market, targeting segments with high growth potential, such as biologics and personalized medicine.
Upturn SWOT Analysis
Strengths
- Strong market position
- Integrated solutions offering
- Focus on innovation and quality
- Global presence
- Long-standing relationships with pharmaceutical companies
Weaknesses
- Dependence on the pharmaceutical industry
- Exposure to raw material price fluctuations
- Potential for product recalls
- High capital expenditure for maintaining facilities
- Exposure to regulatory and environmental issues
Opportunities
- Growing demand for injectable drugs
- Rise of biologics and biosimilars
- Increasing adoption of prefillable syringes and cartridges
- Expansion into emerging markets
- Development of new drug delivery technologies
Threats
- Intense competition
- Pricing pressure from generic drug manufacturers
- Changes in regulatory requirements
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- BDX
- GXI
- WST
Competitive Landscape
Stevanato Group competes on product quality, innovation, and service. It has a strong reputation for providing high-value solutions, but faces competition from larger players with broader portfolios.
Major Acquisitions
Balda AG
- Year: 2016
- Acquisition Price (USD millions):
- Strategic Rationale: Expanded capabilities in plastic solutions for drug delivery.
Growth Trajectory and Initiatives
Historical Growth: Stevanato Group has experienced growth driven by demand for its products and services in the pharmaceutical and life sciences industries.
Future Projections: Future growth projections depend on market conditions and analyst estimates, which require real-time data.
Recent Initiatives: Recent initiatives have included expanding manufacturing capacity, investing in new technologies, and pursuing strategic acquisitions.
Summary
Stevanato Group is a strong player in pharmaceutical packaging due to its integrated solutions and reputation for quality. The growing demand for injectable drugs supports future growth, but competition remains intense. Managing raw material costs and adapting to regulatory changes are crucial for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and estimates. Actual results may vary. Not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stevanato Group SpA
Exchange NYSE | Headquaters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 5521 | Website https://www.stevanatogroup.com |
Full time employees 5521 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.